Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (831-840 of 962) with videos related to

Pageof 97
Sort By:
The American Journal of Cardiology|October 2, 2018
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)Sabato Sorrentino, Gennaro Giustino, Usman Baber, et al.
Journal of the American College of Cardiology|July 5, 2023
P2Y<sub>12</sub> Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary EventsFelice Gragnano, Davide Cao, Leah Pirondini, et al.
JACC. Heart Failure|August 9, 2023
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHFBertram Pitt, Deepak L Bhatt, Michael Szarek, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 20, 2019
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trialPatrick W Serruys, Mariusz Tomaniak, Ply Chichareon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 16, 2020
Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trialHironori Hara, Norihiro Kogame, Kuniaki Takahashi, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Circulation|December 10, 2009
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disordersDavid Attias, Chantal Stheneur, Carine Roy, et al.
European Heart Journal|October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialMichael Szarek, Vera A Bittner, Philip Aylward, et al.
Circulation. Cardiovascular Interventions|March 29, 2020
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS RegistrySabato Sorrentino, Samantha Sartori, Usman Baber, et al.
American Heart Journal|December 3, 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trialGregory G Schwartz, Laurence Bessac, Lisa G Berdan, et al.
Pageof 97

Showing results (831-840 of 962) with videos related to

Sort By:
Pageof 97
The American Journal of Cardiology|October 2, 2018
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)Sabato Sorrentino, Gennaro Giustino, Usman Baber, et al.
Journal of the American College of Cardiology|July 5, 2023
P2Y<sub>12</sub> Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary EventsFelice Gragnano, Davide Cao, Leah Pirondini, et al.
JACC. Heart Failure|August 9, 2023
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHFBertram Pitt, Deepak L Bhatt, Michael Szarek, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 20, 2019
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trialPatrick W Serruys, Mariusz Tomaniak, Ply Chichareon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 16, 2020
Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trialHironori Hara, Norihiro Kogame, Kuniaki Takahashi, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Circulation|December 10, 2009
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disordersDavid Attias, Chantal Stheneur, Carine Roy, et al.
European Heart Journal|October 14, 2020
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trialMichael Szarek, Vera A Bittner, Philip Aylward, et al.
Circulation. Cardiovascular Interventions|March 29, 2020
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS RegistrySabato Sorrentino, Samantha Sartori, Usman Baber, et al.
American Heart Journal|December 3, 2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trialGregory G Schwartz, Laurence Bessac, Lisa G Berdan, et al.
Pageof 97